103 results about "Carcinoma cell line" patented technology

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

The invention provides a veratramine degradation product veratrum fluorene aldehyde 1 and derivatives thereof. The invention uses steroidal alkaloid veratramine (A) as raw material and prepares veratrum fluorene aldehyde by oxidative degradation of m-chloroperoxybenzoic acid to obtain 20 derivative compounds of the veratrum fluorene aldehyde 1 after further oxidation, reduction and condensation reaction. The 20 compounds of the invention have good inhibitory activity on cancer cells, wherein the compounds 1, 2, 5, 8, 13 and 17 have good inhibitory activity on cells of human pancreatic cancer cells BxPC-3 and SW1990, small-cell lung cancer cells NCI-H446, human colorectal cancer LOVO and the like, and the inhibitory activity of the compound veratrum fluorene aldehyde 1 is the most significant.

The invention relates to the field of organic synthesis and medicine, and discloses a preparation method for N-substituted methyl-3,5-disubstituted benzylidene base-4-piperidone and biological activity for efficiently inhibiting cell line proliferation such as leukemia, ovarian cancer, breast cancer, liver cancer and esophagus cancer. The method includes: starting from various substituted methylamine and methyl acrylate, sequentially going through Michael addition, Dieckmann condensation, acidolysis and decarboxylation to obtain N-substituted methyl-4-piperidone, and subjecting the N-substituted methyl-4-piperidone to aldol reaction with substituted benzaldehyde to obtain a target compound N-substituted methyl-3,5-disubstituted benzylidene base-4-piperidone. The target compound can selectively and efficiently inhibit cell line proliferation such as leukemia, ovarian cancer, breast cancer, liver cancer and esophagus cancer, and activity of inhibiting carcinoma cell line proliferation is obviously higher than conventional chemotherapeutic 5-fluorouracil.

The invention discloses a nucleic acid aptamer with a sequence containing DNA (deoxyribonucleic acid) segments shown by any of a sequence 1 and a sequence 2. The nucleic acid aptamer can also be derivatives obtained by various similar sequences high in homology or the sequence. The invention further discloses a screening method of the nucleic acid aptamer. The method includes: synthesizing a random single-strand DNA library and a primer, performing Cell-SELEX screening and PCR (polymerase chain reaction) library amplification, preparing a DNA single-strand library, and obtaining the nucleic acid aptamer through repeated screening, negative screening and several rounds of screening. The nucleic acid aptamer and derivatives thereof can be applied to recognizing human biliary duct carcinoma cell line QBC-939 or preparing a reagent box for detecting the human biliary duct carcinoma cell line QBC-939, has affinity and specificity higher than anti-keratin antibodies, and is free of immunogenicity, capable of being chemically synthesized, small in molecular weight, stable, easy to store and mark, and the like.

Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial and carcinoma cell lines. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.

Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial and carcinoma cell lines. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.

The invention provides a method for detecting endometrial receptivity through MST1 and phosphorylated MST1. The method comprises the steps that a human endometrial carcinoma cell line Ishikawa and HEK293T cells are kept and cultured in a 10% FBS and mycillin containing double-antibody DMEM / F12 culture solution; an immunoblotting experiment is carried out; co-immunoprecipitation is carried out; immunohistochemistry is carried out; adjustment of MST1 on the transcriptional activity of HOXA10 is analyzed through chromosome co-immunoprecipitation (ChIP) / PCRs; human choriocarcinoma cell (BeWo) sphere adhering experiments are carried out. According to the method, the expression level of MST1 and MST1 phosphorylation modification in endometrial tissue is detected conveniently and fast, and the receptivity state of the endometrium can be directly reflected.

The invention belongs to the field of micro-organism animal cell line and relates to a human hepatoma cell line which can emit high-intensity red or green fluorescence and has high transferring ability of lung and lymph node metastasis, and a method for establishing the same. The method comprises the following steps: using the human hepatoma cell line HCCLM3 and HCCLM6 which have high transferring ability of the lung and lymph node metastasis as mother cells, performing cotransfection on plasmid DNA of 239 cells through slow virus packaging plasmids to obtain false slow virus particles by expressing red or green fluorescent protein genes through eucaryon, and infecting liver cancer cell strains of the mother cells to obtain the chromosome integrated hepatoma cell line which has high transferring ability of the lung and lymph node metastasis and can stably expressing the red or the green fluorescence. The human hepatoma cell line which has high transferring ability of the lung and lymph node metastasis in vitro can be applied to the tracer studies on tumor cells, the molecular mechanism studies on the recurrence and transferring of liver cancer, as well as the pre-clinical drug efficacy studies on new anti-tumor drugs, thus the human hepatoma cell line has wide application prospect.

The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL / lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

The invention provides a colorectal carcinoma cell line CJF from hepatic metastasis and a construction method thereof. The obtaining method of the colorectal carcinoma cell line comprises the following steps: obtaining tissues of colorectal carcinoma hepatic metastasis; after digesting the tissues into single cells by using collagenase / hyaluronidase, separating and inoculating CD133+ cells under NOD (Non-Obese Diabetic) / SCID rat skin by MACS (magnetic-activated cell separation); nodulating, and taking out tumor tissues; and culturing in vitro to obtain the colorectal carcinoma cell line CJF which can stably passage and is rich in colorectal carcinoma stem cells. In the invention, CJF cells are obtained from hepatic metastasis of colonic carcinoma patients; compared with other colorectal carcinoma cell lines, the colorectal carcinoma cell line CJF has incomparable advantages for the study of the colonic carcinoma hepatic metastases; cell subsets of the CJF cells for stably expressing the CD133+ cells is about 10 percent; and the action and the research of the colorectal carcinoma cell line in a colorectal carcinoma hepatic metastases process and the tumor stem cells in a metastases mechanism have wide application prospects.

The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL / lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

The invention provides a 2-aminoimidazopyridine derivative shown as a formula I, a formula II, a formula III or a formula IV and further provides a preparation method and application of the 2-aminoimidazopyridine derivative. An experiment shows that the 2-aminoimidazopyridine derivative has a remarkable proliferation inhibition effect on tumor cells (including an over-expressed wild type EGFR (Epidermal Growth Factor Receptor) human epidermal carcinoma cell line A431 and a Gefitinib drug-resisting human lung adenocarcinoma cell line H1975) related to the activity of EGFR tyrosine kinase in the aspect of a cell level, especially has a relatively good inhibition effect on the drug-resisting cell line H1975, has relatively weak inhibition activity on a low-expression EGFR human colon cancer cell line SW620 and can be applied to preparation of corresponding anti-tumor cell medicines. A general formula is shown in the description.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

The invention provides a method for establishing a human nasopharyngeal carcinoma tumor stem cell line. The method comprises the following steps: (1) obtaining human nasopharyngeal carcinoma cells in the single cell state; (2) adding the human nasopharyngeal carcinoma cells in the single cell state, obtained in the step (1), to a serum-free stem cell culture medium containing epidermal growth factors and basic fibroblast growth factors to obtain single cell suspension; (3) adjusting the concentration of the single cell suspension in the step (2) to 900-1100 single cells / ml; (4) inoculating 1ml of the single cell suspension obtained in the step (3) into single pores on a cell culture six-pore plate and then adding the equivoluminal stem cell culture medium for culture for 72-96 hours; and (5) collecting the cells obtained in the step (4), carrying out trypsinization till the single cell and carrying out subculture. The method provided by the invention is simple and convenient to operate; and the obtained nasopharyngeal carcinoma stem cell line has obvious stem cell characteristics.

The invention relates to a method for preparing an alkaloidal compound penicillium enol D2 derived from Penicillium citrinum and an application of penicillium enol D2. The compound has an effect of inhibiting proliferation of tumor cells and has antitumor activity. The structural formula is as shown in the specification. The compound is prepared by the steps: performing fermentation cultivation on Penicillium citrinum IBPT-5, and separating and purifying the compound from the fermented product. The experiment proves that the compound has high antitumor activity on the human lung carcinoma cell line A549. The compound can serve as a medicine for inhibiting cell proliferation or an antitumor drug to be used for antitumor research.

The invention discloses a human lung adenocarcinoma cell line and an application thereof. The human lung adenocarcinoma cell line is preserved at China Center for Type Culture Collection (CCTCC) on May 23th, 2014, in Wuhan University 430072, China. The name of a culture is human lung adenocarcinoma cell ZRLC-1; and a preservation number is CCTCC NO: C2014103. The human lung adenocarcinoma cell ZRLC-1 can be used as an experimental material in lung adenocarcinoma basic and clinical research, and can be used for establishing an animal model for occurrence, development and metastasis of lung cancers. The human lung adenocarcinoma cell line has stable characters, can be sub-cultured for a plurality of times stably, and can highly express epithelial markers such as EpCAM and E-cadherin. Flow cytometric analysis shows that EpCAM positive cells reach over 99.70%; and novel experiment material closer to the biological characteristics of clinical tumors are provided for the research of the lung cancers.

The invention provides a B-norcholestane benzimidazole compound as well as a preparation method and application thereof. The general structural formula of the compound is as shown in the specification, wherein R refers to any one of H or COCH3; R1 refers to F, NO2, CF3, H, CH3 or OCH3; and R2 refers to H or CH3. The B-norcholestane benzimidazole compound disclosed by the invention has high inhibitory activity on human cervical carcinoma cell lines, human lung carcinoma cell lines and human liver cancer cells. The B-norcholestane benzimidazole compound disclosed by the invention is low in toxicity and low in injury of normal cells, has an effective effect of inhibiting the cancer cells during low concentration, basically does not cause drug injury to normal cells and can be applied to preparing medicines for treating the cancers.

The invention provides 2, 3, 5, 7-tetrasubstituted dihydro-pyrazolo piperidine derivative and a preparation method and application thereof. The derivative is 2, 3-bis(substituted phenyl)-5-subsituted arylmethyl-7-substituted benzylidene dihydro-pyrazolo piperidine derivative, having the following formula (I). The preparation method includes using substituted arylmethyl amine and methyl acrylate as raw materials; subjecting the materials to Michael addition, Dieckmann condensation and hydrolysis-decarboxylation sequentially; allowing for Aldol reaction with substituted benzaldehyde to obtain intermediate N-substituted arylmethyl-3, 5-bis(substituted benzylidene)-4-piperidone; allowing for condensation with substituted phenylhydrazine to obtain a compound according to the formula (I). The derivative is efficient in inhibiting multiplication of various carcinoma cell lines such as leukemia, esophagus cancer, ovarian cancer and breast cancer in human, is well stably metabolic in liver microsomes of human and rat, is free of direct and competitive inhibition on five enzymes of liver microsomes, such as CYP3A4, CYP2D6, CYP2C9, CYP1A2 and CYP2C19, is highly bioavailable, is low in toxicity to normal cells, and is available for the preparation of drugs for the cancers.

The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.

Human breast carcinoma SK-BR-3 cell strain as source cell for building train adapted by the invention is continuously inoculated on female NOD / SCID mouse mammary gland fat pad and filtered in pressure of low dose chemotherapy drug tail intravenous injection to build human breast carcinoma cell line SK-3rd rich in tumour breast carcinoma stem cell. The proper of knub stem cell in the cell is increased greatly comparing with non NOD / SCID vivo passage source cell. The formation rate of saccule and the number of cell in the saccule are increased greatly in case of cell suspension culture. The ratio of undifferentiation cancer cell is reduced but is higher evidently than source cell in process of SK-3rd saccule cell inducing differentiation. The saccule cell formed from SK-3rd cell has carcinoma stem cell phenotype which gradually dies out in process of differentiation. NOD / SCID mouse orthotopic transplantation has high tumour-forming rate, high long-distance transferring rate, short tumour-forming periodic time and less number of cells needed by tumour-forming. The invention is an ideal mould for studying breast carcinoma stem cell and has wide applications foreground for disclosing generation mechanism of breast carcinoma and neoplastic treat.

The invention relates to a ferrocene derivative shown as a formula (IA) or a formula (IB) or a pharmaceutically-acceptable salt or a solvate and a medicinal composition thereof. In the formula, R is independently selected from hydrogen, halogen, a cyano-group, a nitro-group, alkyl with 1 to 6 carbon atoms, alkoxy with 1 to 6 carbon atoms, hydroxyl-alkyl with 1 to 6 carbon atoms, halogenated alkyl with 1 to 6 carbon atoms, halogenated alkoxy with 1 to 6 carbon atoms, or alkoxy with 1 to 6 carbon atoms; Z is selected from O, S or NR1; R1 is hydrogen or alkyl with 1 to 6 carbon atoms independently; n is an integer of 0 to 5. The invention further provides a preparation method and medical application of the compound shown as the formula (IA) or the formula (IB) or the pharmaceutically-acceptable salt thereof. The compound has very high restraining activity specific to a lung cancer cell line A549, a colorectal carcinoma cell line HCT116 and / or a breast cancer cell line MCT-7, has broad-spectrum anti-cancer activity, and can be taken as a candidate compound or a lead compound for treating tumor diseases or cancer diseases. The derivative is shown in the description.

The invention discloses epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) NXGF and NXGH with antineoplastic activity and a preparing method and application thereof, and belongs to the field of biological medicine. The brand new EGFR TKI are obtained by optimizing and improving the chemical structure of Pelitinib and named NXGF (the formula I) and NXGH (the formula II) respectively. It is shown through research that the synthesized EGFR TKI-NXGF and the synthesized EGFR TKI-NXGH can effectively inhibit proliferation of tumor cells, have a higher proliferation inhibiting effect on the mutation EGFR lung cancer cell line HCC827 compared with Pelitinib, and thus can be clinically applied as an antineoplastic agent. The invention further discloses the preparing method of the EGFR TKI NXGF and NXGH with antineoplastic activity. By proposing the EGFR TKI NXGF and NXGH with antineoplastic activity, and the preparing method and application thereof, an effective technical means is provided for treating tumors and especially non-small cell lung cancer.

The invention discloses an EGFR (epidermal growth factor receptor) TKI (tyrosine kinase inhibitor) BF3-AZD9291 with anti-tumor activity as well as a preparation method and application thereof, and belongs to the field of biomedicines. By optimizing and improving the chemical structure of AZD9291, a fully new EGFR TKI is obtained, and is named as BF3-AZD9291 (formula I). Proofed by study, the synthesized EGFR TKI BF3-AZD9291 has the advantages that the drug resistance of tumor cells can be effectively inhibited; compared with AZD9291, the stronger drug resistance inhibiting function is realizedfor the mutation EGFR tumor cell line H1975T790M, and the EGFR TKI BF3-AZD9291 can be used as an anti-tumor reagent in clinical application. The invention also discloses the method for preparing theEGFR TKI BF3-AZD9291 with the anti-tumor activity. The EGFR TKI BF3-AZD9291 provides an effective technical method for the treatment of tumors, especially non-small cell lung cancer. (The formula I isshown in the attached figure.).

The invention discloses a human anaplastic thyroid carcinoma cell line and application thereof. The human anaplastic thyroid carcinoma cell line is named as a human anaplastic thyroid carcinoma cell ZJB-ATC1 and is preserved in China Center for Type Culture Collection (CCTCC) in Wuhan University on March 31, 2017, with the preservation number of CCTCC NO: C201753. The human anaplastic thyroid carcinoma cell line disclosed by the invention can be subjected to in vitro passage for a long time, can be amplified to obtain a large quantity of offspring and has relatively strong proliferation activity; a classification type is undifferentiated and can be used as an effective study cell model and a novel experiment model is provided for researchers to deeply develop etiology, a transfer mechanism, a drug-resisting mechanism, new drug screening and the like of human anaplastic thyroid carcinoma.

The invention relates to a 2'-pyrazol-1H-imidazole [4,5-f][1,10] phenanthroline derivate and a preparing method and application thereof. According to the 2'-pyrazol-1H-imidazole[4,5-f][1,10] phenanthroline derivate, different substituted acetophenone and semicarbazlde hydrochloride and 2,4-dinitrobenzene serve as raw materials, the target compound, namely the 2'-pyrazol-1H-imidazole [4,5-f][1,10] phenanthroline derivate is obtained through a five-step reaction, and the obtained target compound is used for applied research of cell line growth inhibition and apoptosis activity for resisting three kinds of cancer cells including the non-small cell lung cancer cell lines A549, human liver cancer cell lines HepG2 and human breast carcinoma cell lines MCF-5. Most compounds can make the experiment cancer cells restrained and apoptotic, high effects are generated on the A549 and HepG2 cell lines are achieved particularly, and selective toxicity on the A549 cell lines is generated particularly. According to the 2'-pyrazol-1H-imidazole [4,5-f][1,10] phenanthroline derivate, a large reference value is provided for finding new anti-tumor micromolecular medicines and is particularly provided for promoting clinical medicine research and development of the phenanthroline derivate.

The invention discloses a human esophageal carcinoma cell line and application thereof. The human esophageal carcinoma cell line is preserved in China Center For Type Culture Collection with a preservation number of CCTCC NO:C201661. Under the premise of retaining the main clinical biological features, the human esophageal carcinoma cell line has the characteristics of high tumor formation rate, short incubation period, good homogeneity and the like, enriches the human esophageal carcinoma cell library, provides powerful scientific research material for study of China population genetic background, and also provides a new experimental material for new drug preclinical study of in vivo and in vitro experiments.

The invention discloses a method for establishing a chicken liver injury cell model, which comprises the following steps: 1) preparing a DMEM / F12 culture medium containing fetal calf serum with the final concentration of 10%, the culture medium containing penicillin and streptomycin; 2) dissolving aflatoxin B1 in a dimethyl sulfoxide solution and diluting the aflatoxin B1 in a dimethyl sulfoxide solution with the culture medium in the step 1), obtaining an induction solution, wherein the final concentration of aflatoxin B1 in the induction solution is 0.05-0.25 microgram / mL, and the final concentration of dimethyl sulfoxide in the induction solution is 0.01-0.025%; 3) culturing the chicken liver cancer cell line until the growth vigor is good and the state is stable; and 4) when the chicken hepatoma carcinoma cell line grows to 70-80% of the adherence, adding the induction liquid in the step 2), and performing induction culture for 6-24 hours to obtain the chicken hepatoma carcinoma cell line.

The invention belongs to the field of microbe animal cell lines, and particularly relates to human biliary tract cancer cell lines and application. The human biliary tract cancer cell lines comprise human biliary tract cancer cell lines which are called a human gallbladder carcinoma cell line ZIJ-0430, a human hilar cholangiocarcinoma cell line ZJU-0826 and a human hilar cholangiocarcinoma cell line ZJU-1125 respectively, and the three human biliary tract cancer cell lines are conserved in the China Typical Culture Conservation Center with the conservation number of CCTCC NO: C2017174, CCTCC NO:C2017175 and CCTCC NO:C2017176 respectively. The human biliary tract cancer cell lines ZJU-0430, ZJU-0826 and ZJU-1125 are built from the source of Chinese people, the line building time is short, the biological inheritance trait is stable, and as study models, the biliary tract cancer cell lines provide great help for knowing a primary biliary tract cancer pathogenesis of Chinese people.